Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Losing weight on GLP-1 drugs like Ozempic isn't guaranteed. Experts reveal how to tell if yours isn't working and the next steps you should take to reach your weight loss goals.

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

CVS Caremark and Express Scripts, along with GoodRx and others, are accused of working together to suppress reimbursements to independent pharmacies in at least three class-action lawsuits. Also, Hims ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Dr Lotte Knudson, a scientist from Copenhagen, revolutionized research into drugs used by millions to lose weight. She has ...

Specifically, the CWR team looked at three years of healthcare data for folks who had just begun taking diabetes drugs like insulin, Ozempic, and the GLP-1 drug liraglutide that's sold under the ...

They were older GLP-1s: albiglutide, dulaglutide, exenatide, liraglutide, and lixisenatide. Semaglutide was also linked to significantly lower Alzheimer's-related medication prescriptions.